What is the recommended dose of intravenous (IV) ceftazidime for the treatment of urinary tract infections (UTIs)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Dosage of Intravenous Ceftazidime for Urinary Tract Infections

For uncomplicated urinary tract infections, the recommended dose of intravenous ceftazidime is 250 mg every 12 hours. For complicated urinary tract infections, the recommended dose is 500 mg every 8 to 12 hours. 1

Dosing Recommendations Based on UTI Type

Uncomplicated UTI

  • 250 mg intravenous every 12 hours 1
  • Treatment duration typically 5-7 days 2
  • Consider oral step-down therapy after clinical improvement 2

Complicated UTI

  • 500 mg intravenous every 8 to 12 hours 1
  • Treatment duration of 7-14 days (14 days for men when prostatitis cannot be excluded) 2
  • Dosage may need adjustment based on local resistance patterns and patient-specific factors 2

Dosage Adjustments for Special Populations

Renal Impairment

  • For creatinine clearance 50-31 mL/min: 1 gram every 12 hours 1
  • For creatinine clearance 30-16 mL/min: 1 gram every 24 hours 1
  • For creatinine clearance 15-6 mL/min: 500 mg every 24 hours 1
  • For creatinine clearance <5 mL/min: 500 mg every 48 hours 1

Hemodialysis Patients

  • Loading dose of 1 gram, followed by 1 gram after each hemodialysis period 1

Pediatric Patients

  • For infants and children (1 month-12 years): 30-50 mg/kg intravenous every 8 hours, to a maximum of 6 grams per day 1
  • For neonates (0-4 weeks): 30 mg/kg intravenous every 12 hours 1

Clinical Considerations for UTI Treatment

Empiric Therapy Considerations

  • Obtain urine culture before initiating therapy to guide subsequent treatment 2
  • Consider local resistance patterns when selecting empiric therapy 2
  • For severe infections or suspected multidrug-resistant organisms, higher doses may be warranted 2

Alternative Agents for UTIs

  • For complicated UTIs caused by carbapenem-resistant Enterobacterales (CRE), ceftazidime-avibactam 2.5 g IV q8h is recommended 2
  • Other options for complicated UTIs include fluoroquinolones, aminoglycosides, or extended-spectrum cephalosporins 2

Duration of Therapy

  • Treatment should generally continue for 2 days after the signs and symptoms of infection have disappeared 1
  • For complicated infections, longer therapy may be required 1

Evidence on Efficacy

  • Clinical studies have demonstrated that ceftazidime is effective for both complicated and uncomplicated UTIs 3
  • In comparative studies, ceftazidime has shown similar efficacy to other parenteral antibiotics for UTIs 4
  • For ceftazidime-resistant pathogens, ceftazidime-avibactam has demonstrated high efficacy in the treatment of complicated UTIs 5, 6

Important Considerations and Pitfalls

  • Ensure appropriate dose adjustment in patients with renal impairment to prevent toxicity 1
  • Do not use ceftazidime for infections caused by known ceftazidime-resistant organisms unless combined with appropriate agents 2
  • Monitor for clinical improvement within 48-72 hours; consider alternative therapy if no response 2
  • For UTIs caused by multidrug-resistant organisms, combination therapy may be necessary 2
  • Generally, ceftazidime should be continued for 2 days after the signs and symptoms of infection have disappeared 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.